# A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

> **NCT00001123** · NA · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 130 (—)

## Conditions studied

- Hantavirus Pulmonary Syndrome

## Interventions

- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00001123
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 130 (—)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001123, "A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00001123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*